Proteomic analysis of human sonic hedgehog (SHH) medulloblastoma stem-like cells by Ronci, Maurizio et al.
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst.
Cite this:DOI: 10.1039/c5mb00034c
Proteomic analysis of human sonic hedgehog
(SHH) medulloblastoma stem-like cells†
Maurizio Ronci,‡abc Giuseppina Catanzaro,‡d Luisa Pieroni,be Agnese Po,d
Zein Mersini Besharat,d Viviana Greco,be Stefano Levi Mortera,be Isabella Screpanti,df
Elisabetta Ferretti*d and Andrea Urbani*be
Human medulloblastoma (MB) is a malignant brain tumor that comprises four distinct molecular
subgroups including the Sonic Hedgehog (SHH)-MB group. A leading cause of the SHH subgroup is an
aberrant activation of the SHH pathway, a developmental signaling that regulates postnatal development
of the cerebellum by promoting the mitotic expansion of granule neural precursors (GNPs) in the
external granule layer (EGL). The abnormal SHH signaling pathway drives not only SHH-MB but also its
cancer stem-like cells (SLCs), which represent a fraction of the tumor cell population that maintain
cancer growth and have been associated with high grade tumors. Here, we report the first proteomic
analysis of human SHH-MB SLCs before and after Retinoic Acid (RA)-induced differentiation. A total of
994 nLC-MS buckets were statistically analysed returning 68 modulated proteins between SLCs and their
differentiated counterparts. Heat Shock Protein 70 (Hsp70) was one of the proteins that characterized the
protein profile of SLCs. By means of Ingenuity Pathway Analysis (IPA), Genomatix analysis and extending the
network obtained using the differentially expressed proteins we found a correlation between Hsp70 and
the NF-kB complex. A key driver of the SHH-MB group is cMET whose downstream proliferation/survival
signalling is indeed via PI3K/Akt/NF-kB. We confirmed the results of the proteomic analysis by western blot,
underlining that a P-p65/NF-kB activatory complex is highly expressed in SLCs. Taking together these results
we define a new protein feature of SHH-MB SLCs.
Introduction
Medulloblastoma (MB) is a malignant brain tumor occurring in
childhood and adults.1 Despite multimodal therapy, MB can
recur and survivors often develop severe long-term neurological
side effects, which have prompted efforts to develop new therapeu-
tic strategies.2 Based on the key developmental signalling pathways,
which regulate MB cells, in recent years high-throughput studies3–10
allowed us to classify MB into four subgroups (WNT-wingless,
SHH-Sonic Hedgehog, Group 3 and Group 4) characterized by
distinct mutations as well as different clinical outcomes.1,6,10,11
The heterogeneity of MB subgroups parallels their recently
identified distinct cells of origin, whose aberrant development
is responsible for tumorigenesis.7,12
In normal development, Hedgehog (HH) functions as a
morphogen to induce cell identities in the ventral spinal cord
and as a mitogen to drive proliferation of granule neural
precursors (GNPs),12 a neuronal cell population that undergoes
proliferation in the external granule layer (EGL) followed by
migration in the internal granule layer (IGL) and differentiation
into mature granules during cerebellar development.13 Activa-
tion of the SHH pathway starts with the interaction of the ligand
with the inhibitory receptor Patched1 (Ptch1), which causes the
depression of the transmembrane transducer Smoothened
(Smo). Following ligand/receptor interaction, Smo migrates to
the top of the cilium, a microtubule based organelle, and
triggers a series of intracellular events that terminates with the
activation of the Gli transcription factors (Gli1, Gli2 and Gli3).
The transcriptional targets regulated by the SHH/Gli pathway
have been in part elucidated and include genes involved in key
cellular processes such as the cell cycle, survival, migration and
metabolism.14
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HH abnormal activation in GNPs leads to the development of
one of the four MB subtypes, SHH-MB.15 SHH-MBs are the most
common MB types in infants and adults, whereas in children
other subgroups are more frequent.11 SHH-MBs in infants,
children, and adults differ in transcriptome, methylome, and
in the number and type of mutations constituting a very hetero-
geneous group of tumors.16 A very recent study showed that
SHH-MBs with tumor relapse and poor survival are characterized
by active MET kinase signaling.17
Stem cells or cancer stem-like cells (SLCs) represent a
fraction of the tumor cell population which are not only the
progenitors that give rise to MB12 and sustain cancer growth,
but have also been associated with poor prognosis in several
kinds of tumors18,19 by driving both resistance to therapy and
disease relapse.12,20 Molecular characterization of human
malignant brain tumors, and in particular SLCs, has identified
a broad spectrum of genes andmolecular mechanisms inhibiting
neuronal and glial differentiation.21
We previously described SLCs derived from human SHH-MBs.22
Since a thorough understanding of the molecular pathways sus-
taining MB SLCs is mandatory to design novel specific therapeutic
strategies, we decided to investigate proteome features of SHH-MB
SLCs and their retinoic acid (RA) differentiated counterparts apply-
ing a novel label-free quantitative proteomic analysis based on a
double stage approach to maximize the identification capacities of
the statistically differential spectral features. Such a technological
workflow is different from the already employed data-independent
differential profiling, which is well assessed and described.23,24 In
fact the two steps allow the increase in the identification capability
of MS/MS data by applying a data dependent acquisition approach
on a limited number of significant spectral features.
Results
Label free differential proteomics of SHH-MB SLCs
Initial studies were performed to evaluate whether the SLCs
could be differentiated through the use of RA treatment. After
48 h of treatment, we were able to detect the presence of
neuronal and glial markers b3-Tubulin and Glial Fibrillary
Acidic Protein (GFAP) respectively. Protein expression of these
markers was confirmed both through western blot and immuno-
fluorescence (Fig. 1A and B).
The statistical analysis of the molecular features (accurate
mass–retention time pairs) extracted from 4 instrumental repli-
cates per condition returned 518 significantly different target
signals at p o 0.05 out of the 944 total reproducible spectral
features included in the statistical evaluation. As shown in the
volcano plot in Fig. 2A and Table S1 (ESI†) they result evenly
distributed between up and down regulated.
Two untargeted MS/MS acquisitions were imported in Protein-
Scape together with the Scheduled Precursor List (SPL) acquisi-
tions and the quantitation tables. Database search was performed
and the results were merged in a single virtual sample.
Proteins whose expression in RA-treated cells versus SLCs
was more than 1.2 times or less than 0.8 fold regulated and that
showed po 0.05 in the difference in the single peptide resulting
in 68 were considered for further processing (Table S2, ESI†). Data
quality was evaluated by checking the analytical performances in
the experimental dataset. In Fig. 2B and C the distribution of the
‘deviation from predictedmass’ at 90% confidence interval in ppm
(RMS90) of accepted identifications (blue) paired to the identifica-
tions that were not accepted (red) and the distribution of the
Mascot score for protein identification (accepted in blue bars and
Fig. 1 SHH-MB SLCs before and after RA-induced differentiation. Western
blot (A) and immunofluorescence (B) analyses of neuronal (b3-Tubulin) and
glial (Glial Fibrillary Acidic Protein, GFAP) markers in SLCs and RA-treated
cells. Exposure to RA for 48 h induced a strong increase in both differentia-
tion markers. In (A) Gliceraldehyde 3-Phosphate Dehydrogenase (GAPDH)
was used as an internal control. In (B) magnification 40, bars 5 mm.
Fig. 2 (A) Volcano plot showing the distribution of significantly differential
signals detected in the MS only chromatographic runs; thresholds are set
to p o 0.05 and a fold change limit of 1.3. (B) Peptide identification
statistics RMS90 [ppm] error distribution, accepted in blue bars and not
accepted in red bars, centered around 6 ppm. (C) Mascot score distribu-
tion of the identified peptides.
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not accepted in red bars) are reported. FDR was set to be less
than 1% from the Mascot search engine results.
A manual and preliminary inspection of the protein data set
confirmed some known evidence and therefore the consistency
of the label free shotgun analysis. For example GFAP_HUMAN,
which is an accepted marker of differentiation, was present
only in RA-treated cells and G3P_HUMAN Glyceraldehyde
3-Phosphate Dehydrogenase (GAPDH), which is known not to
vary with differentiation, resulted not modulated.
Identification of protein networks associated with SHH-MB
SLCs
The identified proteins differentially expressed in SHH-MB
SLCs before and after RA-treatment were used for enrichment
analysis. Tools available at Webgestalt were exploited to obtain
biological insights from the list. The KEGG enrichment analysis
showed that the metabolic pathway (hsa01100; adjP = 4.52 
1011), protein processing in the endoplasmic reticulum pathway
(hsa04141; adjP = 3.86  1013) and glycolysis/gluconeogenesis
pathways (hsa00010; adjP = 2.25  108) were among the most
significantly represented (Table S3, ESI†). Histograms showing
the results of the GO slim classification tool of Webgestalt
Molecular functions, biological processes and cellular compo-
nents are presented in Fig. S1 (ESI†). Interestingly the most
represented ontology in the category biological processes is the
metabolic process.
The list of differential proteins was also subjected to Bio-
profiling. Fig. S2 (ESI†) shows a significant network ( po 0.005)
model generated by the protein–protein Interaction (PPI) spider
tool that analyzes the gene/protein list using as reference the
knowledge of physical associations and direct interactions from
the IntAct database. For the human genome, the reference network
covers about 7960 genes involved in approximately 40000 unique
pairwise interactions. Themodel returns referenced interactions of
the proteins in the dataset allowing 1 missing gene. The resulting
model includes 71 interactions. Database evidence for each inter-
action is reported in Table S4 in the ESI.†
The proteins resulted significantly deregulated were sub-
sequently subjected to pathway analysis using Ingenuity Pathways
Analysis (IPA) in order to assign them to different functional
networks. The top canonical pathways represented in the dataset
resulted in the 14-3-3-mediated signaling, the Remodeling of Epithe-
lial Adherens Junctions, the Glycolysis I, and Gluconeogenesis I. The
activation Z-score predicted among the ‘Disease and Bio Functions’
that ‘cell death of neuroblastoma cell lines’ and ‘cell death of tumor
cell lines’ are decreased (Table 1).
Furthermore, highly significant networks resulting from
IPA (Fig. 3 and Table 2, Fig. S3, ESI†) showed that the NF-kB
complex and p53 are the pivotal players. We selected the
potential biological pathway associated with Hedgehog driven
cancers and stemness networks.
In order to endorse the IPA, we generated a network using
the Genomatix Pathway System (GePS), including differentially
expressed proteins as input (Fig. S4, ESI†). To better evaluate the
connections among pathways highlighted by IPA, we included
transcriptional downstream targets of differentially expressed
proteins in the network. Since tumor cells are cells that are
stressed by a series of stimuli such as hypoxia and oxidative
stress, we focused our attention on Heat Shock Protein 70 (Hsp70)
that resulted over expressed in SLCs. Analysing the network
reported in Fig. 3 we noticed that Hsp70 is connected to Akt
rather than p53. However, since Akt is an upstream regulator of
NF-kB, which is a hub protein in the second significantly
represented network, we decided to further investigate this
important complex. Therefore we performed validation experi-
ments by western blot.
Agreement of differential profiling between commercial
antibodies and MS data
To evaluate the agreement of the potential results achievable with
commercial non-qualified affinity reagents and the specific differ-
ential MS analysis, we selected some biologically relevant proteins
and by means of western blot analysis, we evaluated their abun-
dance in SHH-SLCs and after differentiation (Fig. 4). The results
confirm good agreement between the two methodologies.
Among the functional networks derived from IPA, we analysed
in depth the one connected with the cell death of cancer cells and
we found that hub proteins in this network are mitogen-activated
protein kinase P38 and NF-kB.
P-p65/NF-jB activatory complexes are highly expressed in
SHH-MB SLCs
Since NF-kBwas one of the central nodes in the network analysis, we
further investigated proteins of the NF-kB pathway by western blot
(Fig. 5). We firstly analyzed IKBa, the principal inhibitory protein of
the NF-kB complex, whose phosphorylation results in ubiquitina-
tion, dissociation of IKBa from NF-kB, and eventual degradation of
IKBa by the proteosome followed by nuclear translocation of the
Table 1 IPA results showing the predicted activation Z-score and the molecules involved in the ‘Disease and Bio Functions’
Categories
Diseases or
functions
annotation p-value
Predicted
activation
state
Activation
Z-score Molecules # Molecules
Cell death
and
survival
Cell death of
neuroblastoma
cell lines
3.24  1011 Decreased 2.897 ATP5A1, CCT2, CCT3, CCT5, CCT7, CCT8, ENO1, GAPDH,
HSPA1A/HSPA1B, HSPA8, TCP1, TUBA1A
12
Cell death
and
survival
Cell death of
tumor cell lines
2.40  1012 Decreased 2.178 ALB, ATP5A1, CCT2, CCT3, CCT5, CCT7, CCT8, DTYMK, ENO1,
FAU, GAPDH, HINT1, HNRNPC, HNRNPK, HSP90AB1, HSPA1A/
HSPA1B, HSPA5, HSPA8, HSPA9, LGALS1, LMNA, NPM1, PCNA,
PKM, PPIA, PRDX1, TCP1, TUBA1A, TUBB3, VCP, XRCC6, YWHAZ
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activated NF-kB. We found that IKBa was significantly increased
after RA-induced differentiation (Fig. 5). Conversely phosphoryl-
ated p65 (P-p65), one of the functional subunits of the NF-kB
complex, was highly expressed in SHH-MB SLCs (Fig. 5) while no
change was observed in the expression of total p65 (Fig. 5). These
results define the activation of the NF-kB pathway in SLCs and
its inhibition after differentiation.
Discussion
In this study we focused on the proteomic pattern of SHH-MB
SLCs and their RA-differentiated counterparts. To perform a
differential analysis of the protein repertoire of stem versus
RA-treated differentiated MB cells a novel Label Free Differential
Proteomic workflow based on the detection of the molecular
features was employed.
MB is an aggressive brain tumor,25 which has been stratified
into four subgroups.3 Among them, we focused on the SHH-driven
MB, which is a Hedgehog driven tumor26 and also represents a
high percentage of MB with a bimodal age distribution in infants
(less than 3 years old) and adult population.27 The main purpose
of this study was to shed light on new proteins potentially involved
in the maintenance and/or regulation of cancer stem like cells
derived from such tumors.
The employed peptide-centric differential shotgun profiling
was achieved by targeting only the differential signals. This
approach can provide an in depth view on the repertoire of less
abundant proteins allowing the peptide fragmentation pattern
to be matched with a lower false discovery rate. Such a condi-
tion is simply provided by the employment of a highly specific
MS/MS data dependent acquisition on a limited number of
specific differential signals arising from the statistical filtering.
From a total of 994 profiled buckets before and after
RA-induced differentiation, we have specifically targeted 554
spectral features from which we identified 68 proteins with
significantly altered expression (Tables S1 and S2, ESI†). We
provide evidence of good agreement between MS analysis and
western blotting (Fig. 4), thus confirming the quality of the
employed antibodies and of the MS data. A large number of
proteins significantly increased after differentiation, such as
a-enolase, a typical marker of neuronal terminally differentiated
cells, or GFAP, a marker of glial terminally differentiated cells,
underlining the origin of the tumor from primitive embryonic
neuroepithelial cells able to differentiate both in neuronal or
glial tumor cells.15 While others are involved in cytoskeleton
remodeling, such as vimentin and b-actin, or in energy meta-
bolism, such as malate dehydrogenase mitochondrial or triose-
phosphate isomerase.
Since our aim was to identify proteins characteristic of SHH-
MB SLCs, we mainly focused on proteins, which were down-
regulated in SLCs after RA-induced differentiation. There are many
proteins involved in amino acid metabolism, such as aldolase A;
DNA replication, recombination and repair, such as Proliferating
Cell Nuclear Antigen (PCNA); and cell-to-cell signaling and inter-
action, such as protein disulfide-isomerase A3.
Fig. 3 Graphical representation of the most significant IPA Network (Network # 2; score = 48). NF-kB complex results in a pivotal position. The
connection between Hsp70 and Akt is also evident.
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Among the proteins differentially expressed in SLCs we
further investigated Hsp70 (Table S2, ESI,† and Fig. 4) since it
is known to correlate with poor prognosis in many cancers,
chemotherapy resistance and tumor invasion.28 Hsp70 is a
molecular chaperone, a member of the heat shock protein
family,29 whose production is low or undetectable in unstressed,
healthy cells, but strongly increased upon a variety of stresses,28 such
as free radicals, hypoxia as well as high levels of mutant proteins,
which are highly present in the tumor microenvironment.30
Furthermore, higher expression of Hsp70 has been reported in
large cell MBs compared to classic MBs, and were associated
with worse prognosis.31 Based on our IPA (Fig. 3) and Genomatix
analysis (Fig. S4, ESI†), we found that one of the central regula-
tory molecules in our network was NF-kB. The NF-kB complex is
a family of closely related transcription factors involved in the
regulation of a wide variety of biological responses, such as
immune response and inflammation, cell proliferation and survival
and growing evidence also plays a major role in oncogenesis.32
By means of western blot analysis we showed that IKB-a, the
NF-kB complex main inhibitor, and P-p65, one of the NF-kB
functional subunits, were, respectively, up and down regulated
after RA-induced differentiation (Fig. 5), underlining a role of
this pathway in SHH-MB SLCs.
Incidentally, a recent study has documented that Foretinib,
an orally available multikinase inhibitor, had a dramatic thera-
peutic effect in SHH-MB, both in vitro and in vivo.17 Its activity
was due to the inhibition of the MET kinase, a marker of SHH-MB,
whose activation triggered multiple downstream effector cascade,
Table 2 IPA results showing the most significantly represented networks and the mainly involved diseases and functions
ID Molecules in network Score
Focus
molecules Top diseases and functions
1a ACTB, Actin, ALB, Alpha tubulin, ANXA6, ATP5J, Beta Tubulin, CCT2, CCT3,
CCT5, CCT7, CCT8, DPYSL2, ERK, ERK1/2, FAU, HNRNPC, HNRNPK,
HNRNPU, HSPA5, Laminin, LGALS1, MAP2K1/2, Mek, p85(pik3r), PPIA, Ras,
Rnr, RPS27A, RPSA, TCP1, TUBB, TUBB4B, VIM, YWHAZ
48 24 Cellular assembly and organization,
cell-to-cell signaling and interaction,
reproductive system development and
function
2 26s Proteasome, Akt, ATP5A1, CALD1, CFL1, cytochrome C, ENO1, estrogen
receptor, FABP7, FSH, GAPDH, GFAP, Hsp70, Hsp90, HSP90AA1, HSP90AB1,
HSPA8, HSPA1A/HSPA1B, LMNA, NFkB (complex), NPM1, P38 MAPK, PDIA3,
PKM, RNA polymerase II, STAT5a/b, STIP1, TUBA1A, TUBA1B, TUBB3, UGP2,
VCP, XRCC6, YWHAB, YWHAQ
48 24 Neurological disease, psychological
disorders, cancer
3a AFP, ALDOA, CCNB2, CD9, CITED1, COTL1, CUL4B, DERL1, EEF2, EEF1A1,
ERBB2, FSCN1, GLS, HNRNPU, HSPA9, LAMP2, LDHB, MTBP, MYC, NUDC,
OSMR, PDIA6, PFAS, POLD1, PPAT, PRDX1, RNA polymerase I, SET, TNF, TPI1,
TUBB2B, TWIST2, VARS, XBP1, YBX3
23 14 Amino acid metabolism, small molecule
biochemistry, cell morphology
4a AP2B1, ASL, ATP5B, BCAP31, C2, CDK14, CKB, CLTC, E2F4, GART, GRB2,
HINT1, Histone h3, IFNG, KIAA0101, Lh, MDH2, PCM1, PCNA, POLD1, POLH,
PPARA, PRKCSH, RFC1, RFC3, RPL10, RPL13, RPL26, RPL32, RRM2B, SNX9,
ST13, STAMBP, TOM1, TP53
21 13 DNA replication, recombination, and
repair, cancer, neurological disease
5 AKT2, APTX, ARRB1, B2M, Collagen Alpha1, Collagen type I, CS, CSF2, DBI,
G6PC, Gsk3, H6PD, IDH1, ITGB2, MAPK7, MDH1, MED13, MHC Class II
(complex), MSX2, NR3C1, PPARG, PPARGC1B, PRKAR1A, SERPINA1, SFPQ,
SLC27A1, SPP1, THRA, TKT, TNFRSF1B, TPM4, TSC22D3, UPP1, VDR, YWHAE
6 5 Lipid metabolism, Molecular transport,
small molecule biochemistry
6 DTYMK, MED1 2 1 Nucleic acid metabolism, small molecule
biochemistry, organ morphology
7 PAFAH1B1, PAFAH1B3 2 1 Lipid metabolism, small molecule
biochemistry, cellular development
a Networks are connected; the graphical representation is presented in Fig. S3 (ESI).
Fig. 4 Confirmation of protein spots by western blot. (A) Western blot
analysis of Heat Shock Protein 70 (Hsp70), Proliferating Cell Nuclear
Antigen (PCNA) and a-enolase in SLCs and in 48 h RA-treated cells.
GAPDH was used as a control for equal protein loads. (B) Densitometric
analysis confirmed the significant differential expression observed by
proteomic analysis. The protein expression, normalized to GAPDH expres-
sion, represents the mean  SEM from three independent experiments.
* denotes p o 0.05 versus SLCs.
Fig. 5 RA-induced differentiation regulated NF-kB pathway activation.
(A) IKB-a, P-p65 and p65 expressions were analyzed by means of western
blot after 48 h RA-induced cell differentiation. (B) Densitometric analysis
showed a significant increase in IKB-a expression, while P-p65 was
significantly reduced after RA treatment. Total p65 levels did not change
after differentiation. Protein expression was normalized by GAPDH. The
data represent mean  SEM values from three independent experiments.
* denotes p o 0.05 versus SLCs.
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including PI3K/Akt.17 Since Hsp70 promotes tumor cell survival
and dissemination28 and activates Akt,33 an upstream regulator
of the NF-kB complex,34 we hypothesize that Hsp70 could
be involved in the biological network maintaining SHH-MB
SLCs (Fig. 6).
Taken together, our proteomic results define the human
SHH-MB SLC proteins and signalling networks suggesting new
key biological players involved in the process of malignancy
transmutation.
Experimental procedures
Materials
Unless otherwise indicated, media and supplements were pur-
chased from Gibco-Invitrogen (Carlsbad, CA) and chemicals were
purchased from Sigma-Aldrich (St. Louis, MO).
Culture of SHH SLCs
Human infant (less than 3 years old children) medulloblastoma
samples (MB) were collected during surgical resection with the
approval of institutional review board as described earlier.35
Tissues were collected in Hank’s Balanced Salt Solution (HBSS)
supplemented with 0.5% glucose and penicillin–streptomycin,
grossly triturated with serological pipette and treated with
DNAse I to a final concentration of 0.04% for 20 min. Sub-
sequently, cell aggregates were mechanically disrupted using
pipettes of decreasing pore size to obtain a single cell suspen-
sion. After dissociation and centrifugation, cells were cultured
as neurospheres in selective medium, DMEM/F12 supple-
mented with 0.6% glucose, 60 mg mL1 N-acetyl-L-cysteine,
2 mg mL1 heparin, 20 ng mL1 NGF, 20 ng mL1 bFGF
(Peprotech, Rocky Hill, NJ), 1 penicillin–streptomycin and
B27 supplement without vitamin A.
For differentiation studies, neurospheres were mechanically
dissociated and plated on D-poly-Lysine coated dishes in differen-
tiation medium (DMEM/F12 with N2 supplement and 2 mg mL1
heparin, 0.6% glucose, 60 mg mL1 N-acetyl-L-cysteine, containing
1% fetal bovine serum and RA 8 mM) for 48 h. All samples were
prepared in 3 biological replicates for each point.
Protein extraction and digestion
Cells were lysed in Tris-HCl pH 7.6, 50 mM, NaCl 150 mM,
EDTA 1 mM, Triton X-100 1% and a protease inhibitor cocktail
(SIGMA P8340). Extracted proteins were precipitated in 80%
acetone, ON at 20 1C.
Washed protein pellets were subsequently resuspended in a
denaturing solution (6 M urea in 100 mM Tris-HCl pH 7.8)
compatible with trypsin digestion that was conducted as pre-
viously described.23
Label free data dependent shotgun proteomic analysis
The samples were diluted with an aqueous solution of 0.1% FA,
3% CH3CN to a final peptide concentration of 0.4 mg mL
1 and
analyzed by nanoLC-MS on a Proxeon EASY-nLCII (Thermo
Fisher Scientific, Milan, Italy) interfaced with a maXis HD
UHR-TOF mass spectrometer (Bruker Daltonics GmbH, Bremen,
Germany). 2 mL of the sample were injected for the MS only runs
whereas 5 mL for the MS/MS runs. Samples were pre-concentrated
on a C18-A1 EASY-Columnt (2 cm, 100 mm I.D., 5 mm p.s.,
Thermo Fisher Scientific) for 1 min at a flow rate of 10 mL min1.
Trapped peptides were subsequently separated using a gradient
elution on a C18-Acclaim PepMap (25 cm, 75 mm I.D., 5 mm p.s.,
Thermo Fisher Scientific). Flow rate: 0.3 mL min1, T 20 1C;
eluents: A, 0.1% FA in H2O and B, 0.1% FA in CH3CN; gradient:
from 2 to 45% B in 130 min.
Mass spectrometry data were acquired according to the novel
label free quantitation workflow developed by Bruker Daltonics.
Fig. 6 Hypothesis of the role of Hsp70 in SHH-MB SLCs. A variety of stresses (reactive oxygen species, hypoxia, elevated temperature, altered pH)
activate Hsp70. Hsp70 induces Akt, which acts as an upstream regulator of the NF-kB complex (a classical pathway), leading to p65 phosphorylation and
its nuclear translocation and resulting in the deregulation of proliferation and survival.
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Briefly, each sample was first acquired in the MS mode and in
triplicate to detect the ‘molecular features’. Raw data were
processed using the software DataAnalysis v.4.2 to generate a
mass list with only exact masses, retention times and intensities.
A bucket table was subsequently constructed using ProfileAnalysis
v.2.1 (build 268) and a T-test performed to highlight the statisti-
cally significant differences between the signals detected in each
condition. In order to be considered for further processing the
molecular features had to satisfy the conditions of a satisfactory
replication rate (at least in 4 out of 8 total runs, 50% and at least in
3 out of 4 replicates, 75%) and po 0.05 for the relative signal fold
change (two-tailed Student’s T test). The software automatically
generated a list of signals to be included in a scheduled precursor
list (SPL) to be targeted in the following MS/MS runs. The
samples were then acquired in the MS/MS mode to obtain
sequence information of the differential signals. Raw MS/MS
data were also processed using DataAnalysis v.4.2 to generate
the .xml file for further processing database searching. The
quantitation tables together with the MS/MS mass lists were
imported in ProteinScape v.3.1.5 474 (Bruker Daltonics GmbH,
Bremen, Germany), which was used to perform both protein
identifications, protein assessment and linking of the IDs with
the bucket tables in order to obtain a list of proteins with the
corresponding fold changes. Protein IDs were performed using
the MASCOT v.2.4.1 algorithm (http://www.matrixscience.com),
against the Uniprot/Swiss-Prot non-redundant database version
2013-08 restricted to Homo sapiens taxonomy (20266 sequences),
setting carbamidomethylation of cysteine as fixed modification and
the oxidation of methionine as variable modification, allowing two
missed cleavages. A maximal error tolerance of 10 ppm for the
precursors and 0.05 Da for the fragment ions were selected accord-
ing to the high resolution of the mass analyzer. Protein list compila-
tion and assessment were performed using the ProteinExtractor
algorithm implemented in ProteinScape setting the following thres-
holds: the ion score cut-off to 15.0, the Mascot protein scores to
30 ( p o 0.05) and the Mascot peptide score to 25.
In order to identify significant up- or down-regulation the
differentially expressed protein dataset was filtered to a thres-
hold of 20%, hence 1.2-fold, which is typically 2 times higher
than the estimated error in the intensity measurement.
Bioinformatics and statistical analysis
The Gene Ontology, the KEGG pathway, the Wikipathway and
the disease association enrichment analyses were carried out
using the Webgestalt online tools (http://bioinfo.vanderbilt.
edu/webgestalt/) using the entire Homo sapiens genome as a
reference set. Fisher’s exact test with the Benjamini & Hochberg
adjustment for multiple comparisons was employed to control
the threshold of statistical overrepresentation of biochemical
pathways. The 10 pathways with the most significant p values
were considered. The list of the differential proteins was also
analysed with BioProfiling (http://www.bioprofiling.de/) to obtain
the network enrichment, based on known physical protein–protein
interactions (IntAct Database). The significant analyses, po 0.01,
were further considered to interpret and discuss proteomic results.
The estimate of the p-value provided by theMonte Carlo procedure
corresponds to the probability to get a model of the same
quality for a random gene list of the same size (random
networks statistical environment). Eventually, the enriched net-
work was exported as .xgmml file and visualized and modified
by Cytoscape (http://www.cytoscape.org/).
Protein network analysis was performed through the use of
QIAGEN’s Ingenuitys Pathway Analysis (IPAs, QIAGEN Redwood
City,www.qiagen.com/ingenuity). IPA constructs hypothetical pro-
tein interaction clusters based on the Ingenuity Pathways Knowl-
edge Base. Direct and indirect relationships between the identified
proteins were shown as networks on the base of all genes, and
endogenous chemicals present in the Ingenuity Knowledge
Network scores are calculated as log(p-value) and indicate
the likelihood that focus genes (i.e., the identified proteins
within a specific network) are clustered together. Biological
functions and canonical pathways over-represented among the
identified proteins were also assigned to networks stored in the
Ingenuity Pathways Knowledge Base. Biological functions and
canonical pathways were ranked in accordance to their signifi-
cance. Significance was evaluated by an exact Fisher’s test.
The list of differentially expressed proteins was used as input
for the Genomatix Pathway System (GePS, v.2.7.0, Genomatix
Genome Analyzer, v.3.20715). The Median score (Stem, SLCs:
Differentiated, RA) was used as a value of expression. Hsp70 was
selected and extended once with transcription factors. Based on
this first obtained network, NF-kB (NFKB1) and TP53 were selected
and extended once with transcriptional downstream targets pro-
ducing the final network.
Western blot densitometry data were expressed as mean 
S.E.M. of at least three independent experiments, each per-
formed in triplicate. Student’s T test was performed to evaluate the
significance of the differences and experimental data elaborated
by means of the GraphPad Prism 5 software (GraphPad Software
for Science, San Diego).
Immunochemical analysis
Cells were lysed in Tris-HCl pH 7.6, 50 mM, deoxycholic acid
sodium salt 0.5%, NaCl 140 mM, NP40 1%, EDTA 5 mM, NaF
100 mM, Na pyrophosphate 2 mM and protease inhibitors. For
phospho p65, 2 mM Na orthovanadate and 5 mM Na butyrate
were also added. Lysates were separated on 8% or 10% acryl-
amide gel and immunoblotted using standard procedures.
Rabbit anti-Hsp70, sc-33575 (Santa Cruz Biotechnology, CA), rabbit
anti-PCNA, #13110 (Cell Signaling Technology Inc., Danvers, MA);
mouse anti-b3-tubulin (TU-20), #4466 (Cell Signaling Technology
Inc, Danvers, MA); mouse anti-GFAP, MAB360 (Merck Millipore,
Darmstadt), rabbit anti-p65, #3034S (Cell Signaling Technology
Inc, Danvers, MA); rabbit anti-phospho p65 (P-p65), #3033S
(Cell Signaling Technology Inc, Danvers, MA); mouse anti-GAPDH,
ab8245 (AbCam, Cambridge, UK) and HRP-conjugated secondary
antisera (Santa Cruz Biotechnology, CA) were used followed by
enhanced chemiluminescence (ECL Amersham, Amersham, UK)
and images were acquired using the BioRad ChemiDoc
MP Imaging System (BioRad, Hercules, CA). Densitometric
analysis was performed using the BioRad associated Image
Lab Software (BioRad, Hercules, CA). Values are expressed as
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fold over internal control, represented by GAPDH, that does not
change significantly in the proteome profiles.
Immunofluorescence analysis
For immunofluorescence studies, neurospheres were plated
on D-poly-lysine coated Lab-Tek chamber slides and allowed
to adhere for 3 h. RA-differentiated MB cells (RA) were mechani-
cally dissociated, plated on D-poly-lysine coated Lab-Tek chamber
slides and cultured in differentiating medium for 2 days. Cells
were fixed with 4% paraformaldehyde for 10 min at RT, incubated
in permeabilization (0.1% Triton X-100) followed by blocking
buffer (5% bovine serum albumin, BSA) and stained overnight
with primary antibodies and for 1 h with secondary antibodies,
both diluted in blocking solution. Primary antibodies were mouse
anti-b3-Tubulin (TU-20), #4466 (Cell Signaling Technology Inc,
Danvers, MA) and mouse anti-GFAP, MAB360 (Merck Millipore,
Darmstadt). 488-conjugated anti-mouse secondary antibody was
purchased from Molecular Probes (Invitrogen, Eugene, OR).
Nuclei were counterstained with a Hoechst reagent. Coverslips
were mounted with fluorescence mounting medium (S3023,
Dako, Carpinteria, CA). Images were acquired using a Carl Zeiss
microscope (Axio Observer Z1) using Apotome technology and
AxioVision Digital Image Processing Software.
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